{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:07:10Z","timestamp":1772993230489,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jiac.2024.12.005","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T17:53:26Z","timestamp":1733334806000},"page":"102576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2364-1153","authenticated-orcid":false,"given":"Pengfei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jiac.2024.12.005_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc2297","article-title":"Diagnosing and exploiting cancer's addiction to blocks in apoptosis","volume":"8","author":"Letai","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.jiac.2024.12.005_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.jiac.2024.12.005_bib3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.bcp.2008.06.009","article-title":"Bcl-2 family members as molecular targets in cancer therapy","volume":"76","author":"Marzo","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.jiac.2024.12.005_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J Personalized Med"},{"issue":"2","key":"10.1016\/j.jiac.2024.12.005_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nm.3076","article-title":"Apoptosis therapy: driving cancers down the road to ruin","volume":"19","author":"Green","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jiac.2024.12.005_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jiac.2024.12.005_bib7","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jiac.2024.12.005_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.jiac.2024.12.005_bib9","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.jiac.2024.12.005_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-022-00770-x","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis","volume":"12","author":"Kwag","year":"2022","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jiac.2024.12.005_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jiac.2024.12.005_bib12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jiac.2024.12.005_bib13","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jiac.2024.12.005_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jiac.2024.12.005_bib15","series-title":"Flavida chemotherapy induces MRD-negative remission in patients with relapsed\/refractory acute myeloid leukemia","first-page":"S139","author":"Shahswar","year":"2021"},{"key":"10.1016\/j.jiac.2024.12.005_bib16","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1016\/S2152-2650(22)01306-4","article-title":"AML-491 real world practice of FLAG-idarubicin-venetoclax in relapsed refractory AML: a single center experience","volume":"22","author":"Lee","year":"2022","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"14","key":"10.1016\/j.jiac.2024.12.005_bib17","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jiac.2024.12.005_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.18051","article-title":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","volume":"197","author":"On","year":"2022","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.jiac.2024.12.005_bib19","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood-2019-127423","article-title":"Management of neutropenia during venetoclax-based combination treatment in patients with newly diagnosed acute myeloid leukemia","volume":"134","author":"Pratz","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jiac.2024.12.005_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278725","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax","volume":"17","author":"Yang","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jiac.2024.12.005_bib21","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jiac.2024.12.005_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40588-018-0098-6","article-title":"The role of neutrophils in host defense against invasive fungal infections","volume":"5","author":"Desai","year":"2018","journal-title":"Curr Clin Microbiol Rep"},{"issue":"1","key":"10.1016\/j.jiac.2024.12.005_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/imr.12454","article-title":"How neutrophils kill fungi","volume":"273","author":"Gazendam","year":"2016","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2014-01-551473","article-title":"Two independent killing mechanisms of Candida albicans by human neutrophils: evidence from innate immunity defects","volume":"124","author":"Gazendam","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1462-5822.2005.00659.x","article-title":"Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms","volume":"8","author":"Urban","year":"2006","journal-title":"Cell Microbiol"},{"issue":"165","key":"10.1016\/j.jiac.2024.12.005_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jiac.2024.12.005_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.2000.02014.x","article-title":"Towards a targeted, risk-based, antifungal strategy in neutropenic patients","volume":"110","author":"Prentice","year":"2000","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.jiac.2024.12.005_bib28","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1200\/JCO.2008.21.0856","article-title":"Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve","volume":"27","author":"Portugal","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jiac.2024.12.005_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-100-3-345","article-title":"Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia","volume":"100","author":"Gerson","year":"1984","journal-title":"Ann Intern Med"},{"issue":"23","key":"10.1016\/j.jiac.2024.12.005_bib30","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.jiac.2024.12.005_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246285","article-title":"Infections of venetoclax-based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.jiac.2024.12.005_bib32","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jiac.2024.12.005_bib33","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00277-022-04883-y","article-title":"Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis","volume":"101","author":"Wolach","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jiac.2024.12.005_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jiac.2024.12.005_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac486","article-title":"Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine","volume":"9","author":"Zhang","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2024.12.005_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jiac.2024.12.005_bib38","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.jiac.2024.12.005_bib39","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jiac.2024.12.005_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107341","article-title":"Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?","volume":"131","author":"Guarana","year":"2023","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jiac.2024.12.005_bib42","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/cid\/ciac230","article-title":"Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies","volume":"75","author":"Rausch","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jiac.2024.12.005_bib43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jiac.2024.12.005_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad134","article-title":"Breakthrough invasive fungal infection after coadministration of venetoclax and voriconazole","volume":"10","author":"Hall","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib45","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jac\/dku477","article-title":"A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients","volume":"70","author":"Br\u00fcggemann","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.jiac.2024.12.005_bib46","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1093\/jac\/dky324","article-title":"Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis","volume":"73","author":"Muilwijk","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"suppl_1","key":"10.1016\/j.jiac.2024.12.005_bib47","doi-asserted-by":"crossref","first-page":"i60","DOI":"10.1093\/jac\/dkx450","article-title":"Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies","volume":"73","author":"Epstein","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jiac.2024.12.005_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jinf.2018.03.015","article-title":"Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study","volume":"77","author":"Epstein","year":"2018","journal-title":"J Infect"},{"issue":"Suppl 6","key":"10.1016\/j.jiac.2024.12.005_bib49","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1093\/cid\/civ818","article-title":"Safety and efficacy of intermittent intravenous administration of high-dose micafungin","volume":"61","author":"Neofytos","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib51","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/bjh.19116","article-title":"Invasive fungal infection following venetoclax and posaconazole co-administration","volume":"203","author":"Reynolds","year":"2023","journal-title":"Br J Haematol"},{"issue":"Suppl 7","key":"10.1016\/j.jiac.2024.12.005_bib52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern Med J"},{"issue":"8","key":"10.1016\/j.jiac.2024.12.005_bib53","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/myc.13100","article-title":"Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever","volume":"63","author":"Yoshida","year":"2020","journal-title":"Mycoses"},{"issue":"9","key":"10.1016\/j.jiac.2024.12.005_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad424","article-title":"Real-world use of mold-active triazole prophylaxis in the prevention of invasive fungal diseases: results from a subgroup analysis of a multicenter national registry","volume":"10","author":"Nguyen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2024.12.005_bib55","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040694","article-title":"Interaction of antifungal drugs with CYP3A- and OATP1B-mediated venetoclax elimination","volume":"14","author":"Eisenmann","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.jiac.2024.12.005_bib57","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/jcph.730","article-title":"Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study","volume":"56","author":"Agarwal","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jiac.2024.12.005_bib58","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharmaceut Sci"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib59","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma","volume":"83","author":"Agarwal","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00228-017-2403-3","article-title":"Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics","volume":"74","author":"Freise","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jiac.2024.12.005_bib61","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Therapeut"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib62","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00280-020-04179-w","article-title":"Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach","volume":"87","author":"Bhatnagar","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.jiac.2024.12.005_bib63","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s11095-022-03289-9","article-title":"Development of physiology based pharmacokinetic model to predict the drug interactions of voriconazole and venetoclax","volume":"39","author":"Dong","year":"2022","journal-title":"Pharm Res (N Y)"},{"issue":"6","key":"10.1016\/j.jiac.2024.12.005_bib64","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jcph.858","article-title":"Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model","volume":"57","author":"Freise","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jiac.2024.12.005_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26707","article-title":"Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study","volume":"97","author":"Jonas","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jiac.2024.12.005_bib66","first-page":"75","article-title":"Real-life experience of dose-adjusted venetoclax in acute myeloid leukemia patients concomitantly using posaconazole for antifungal prophylaxis: a single-center experience","volume":"33","author":"Iltar","year":"2023","journal-title":"Int J Hematology Oncol"},{"key":"10.1016\/j.jiac.2024.12.005_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106837","article-title":"Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission","volume":"116","author":"Nguyen","year":"2022","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.jiac.2024.12.005_bib68","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s00277-020-04168-2","article-title":"Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia","volume":"99","author":"Cheng","year":"2020","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.jiac.2024.12.005_bib69","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jiac.2024.12.005_bib70","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40273-017-0599-9","article-title":"Venetoclax for treating chronic lymphocytic leukaemia: an evidence review group perspective of a NICE single technology appraisal","volume":"36","author":"Mistry","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jiac.2024.12.005_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27051607","article-title":"Quantification of venetoclax for therapeutic drug monitoring in Chinese acute myeloid leukemia patients by a validated UPLC-MS\/MS method","volume":"27","author":"Yang","year":"2022","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.jiac.2024.12.005_bib73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12032-022-01865-y","article-title":"Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia","volume":"39","author":"Kobayashi","year":"2022","journal-title":"Med Oncol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24003234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24003234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:48:47Z","timestamp":1738928927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24003234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1341321X24003234"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.12.005","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102576"}}